05.12.2012 - Baxter International Inc. strengthens its dialysis business with the acquisition of Swedish Gambro AB.
Private equity investors sold the firm for about US-$4bn. Gambro has a product portfolio in global home dialysis. The acquisition positions Baxter as the worldwide number two in the dialysis market. The Swedish firm had about US$1.6bn in sales last year. Gambro is owned by Sweden’s EQT Partners AB and Investor AB which is the investment firm controlled by Sweden’s billionaire Wallenberg family.
According to sources, the negotiations started as early as one year ago.Matt Miksic, analyst with Piper Jaffray, welcomed the acquisition in a telephone interview with Bloomberg. “Baxter's renal division is a little bit undersized relative to some of their other businesses; this balances that a bit and gives it a little more weight.” “Both companies have a longstanding heritage in kidney care with innovative technologies and a dedication to saving, sustaining and improving the lives of patients worldwide,” said Guido Oelkers, president and chief executive officer of Gambro.
According to Baxter dialysis is a market that grows by more than 5% per year. The Gambro deal is a further step in the consolidation of the kidney dialysis market, where Gambro and Baxter compete against companies including U.S.-based DaVita HealthCare Partners Inc and Germany's Fresenius Medical Care AG. Baxter manufactures kidney dialysis equipment, drug infusion pumps and blood therapy products. The Gambro acquisition will round out Baxter's renal business, which accounted for almost one-fifth of the company's 2011 revenue of US-$13.89bn.
03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.
02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.
30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.
12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.
METTLER TOLEDO now offers a new family of high-precision weighing platforms that provide superior accuracy and reliability in harsh industrial conditions with flexibility to be used for many applications. more